Tuesday, August 4, 2026
Vertex tops Q2 estimates, raises 2026 revenue guidance
Vertex Pharmaceuticals reported Q2 2026 revenue of $3.33 billion on August 3, up 12% year over year, with net income of $1.10 billion and EPS of $4.34. The company raised full-year 2026 revenue guidance to $13.1-13.2 billion, driven partly by CASGEVY revenue growing 151% year over year to $76 million and JOURNAVX revenue roughly quadrupling to $50 million, with the two products now expected to contribute over $500 million combined for the year.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.
/ Related
- Court says Vertex Casgevy fertility perk is a kickbackSaturday, September 5, 2026
- Vertex closes $10 billion Crinetics acquisitionWednesday, September 2, 2026
- Crinetics shareholders approve Vertex's $10 billion buyoutTuesday, September 1, 2026
- Court clears Lupin's generic Kalydeco in Vertex patent fightThursday, August 27, 2026